Skip to main content
Top
Published in: BMC Neurology 1/2019

Open Access 01-12-2019 | Fabry Disease | Case report

Central nervous system vasculopathy caused by Fabry disease: a case report

Authors: De-Zheng Kong, Ya-Hui Lian, Lin-Jing Wang, Chun-Mei Wang, Yang-Yang Meng, Hong-Wei Zhou

Published in: BMC Neurology | Issue 1/2019

Login to get access

Abstract

Background

Fabry disease is rare, and the diagnosis is often delayed. Here, we describe a case of Fabry disease resulting in vasculopathy of the central nervous system. Magnetic resonance (MR) black-blood sequence (three-dimensional T1 volumetric isotropic turbo spin echo acquisition), with the unique advantage of imaging the vascular wall, facilitated a clear identification of the vasculopathy.

Case presentation

A 27-year-old man visited our hospital for the treatment of “ double vision 6d.” After a series of examinations, the patient was diagnosed with Fabry disease, which caused vasculopathy of the central nervous system. Subsequently, the patient was treated with corticosteroids and his symptoms were attenuated. Two months after the initial treatment, the initial lesion in the vascular vessel disappeared, however, a new lesion appeared. Similarly, four months after the initial treatment, although the previous lesion disappeared, a new lesion appeared.

Conclusions

This case highlights that clinicians should use MR black-blood sequence scan in a timely manner in case of young patients with migratory lesions of brain. In case of detection of a vascular lesion in combination with other systemic lesions, the possibility of Fabry disease should be considered.
Literature
1.
go back to reference Poorthuis BJHM, Wevers RA, Kleijer WJ, Groener JEM, de Jong JGN, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999;105(1–2):151–6.CrossRef Poorthuis BJHM, Wevers RA, Kleijer WJ, Groener JEM, de Jong JGN, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999;105(1–2):151–6.CrossRef
2.
go back to reference Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.CrossRef Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.CrossRef
3.
go back to reference Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis. 2007;30(2):184–92.CrossRef Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis. 2007;30(2):184–92.CrossRef
4.
go back to reference Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ. Twenty novel mutations in the alpha-galactosidase a gene causing Fabry disease. Mol Med. 1999;5(12):806–11.CrossRef Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ. Twenty novel mutations in the alpha-galactosidase a gene causing Fabry disease. Mol Med. 1999;5(12):806–11.CrossRef
5.
go back to reference Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat. 2001;18(5):459.CrossRef Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat. 2001;18(5):459.CrossRef
6.
go back to reference Maier E, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, Roscher A, Muntau A. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr. 2006;95:30–8.CrossRef Maier E, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, Roscher A, Muntau A. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr. 2006;95:30–8.CrossRef
7.
go back to reference Salviati A, Burlina AP, Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010;31(3):299–306.CrossRef Salviati A, Burlina AP, Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010;31(3):299–306.CrossRef
Metadata
Title
Central nervous system vasculopathy caused by Fabry disease: a case report
Authors
De-Zheng Kong
Ya-Hui Lian
Lin-Jing Wang
Chun-Mei Wang
Yang-Yang Meng
Hong-Wei Zhou
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Fabry Disease
Published in
BMC Neurology / Issue 1/2019
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-019-1348-9

Other articles of this Issue 1/2019

BMC Neurology 1/2019 Go to the issue